Skip to main content
Premium Trial:

Request an Annual Quote

Counsyl Raises $28M, Launches BRCA1/2 Testing

NEW YORK (GenomeWeb) – Genetic testing firm Counsyl today announced it raised $28 million in a Series D financing, and it has launched its BRACA1 and BRCA2 screening service.

The financing was co-led by Rosemont Seneca Technology Partners and Goldman Sachs Asset Management and brings the total amount raised by South San Francisco, Calif.-based Counsyl to $93 million, it said. The company will use the funds for product development.

The company also announced the launch of its Inherited Cancer Screen service, starting with the BRCA1/2 genes. The launch comes about seven months after Counsyl sought declaratory judgment from a California federal court that it wouldn't infringe on Myriad Genetics' BRCA1/2 patent claims if it offered testing for the genes. The company said that several claims in Myriad's patents had been invalidated by the US Supreme Court and by the US Court of Appeals for the Federal Circuit, giving Counsyl the right to test for BRCA gene alterations associated with the hereditary risk of breast and ovarian cancer.

The lawsuit has been centralized into one action that includes litigation by Quest Diagnostics and InVitae, which also sought judgments against Myriad that they don't infringe Myriad's patents. The case has been transferred to the US District Court for the District of Utah.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more